Last updated on September 2016

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention


Brief description of study

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention

Detailed Study Description

This study will evaluate safety and tolerability of the of the different doses of investigational medication for prevention of episodic migraine.

Clinical Study Identifier: TX145503

Find a site near you

Start Over

SPRI Clinical Trials Brooklyn

3044 Coney Island Ave., ste. 201 Brooklyn, NY USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.